Browse drugs

… among the GLP-1RA group compared with the sulfonylureas group. GLP-1RA=glucagon-like peptide-1 receptor agonistsDiscussionIn this nati…

…nsporter 2 inhibitors, and insulin, as well as length of use of metformin, sulfonylureas, thiazolidinediones, dipeptidyl peptidase 4 inhi…

…ever, these studies did not employ suitable active comparators. Metformin is often prescribed as first-line therapy in T2DM management, w…

…ltiple risk factors for cardiovascular disease, irrespective of metformin use.14–19Despite the demonstrated benefits of SGLT2i and GLP-1R…

…s associated with 11.9% greater weight reduction (13 RCTs), and tirzepatide was associated with 16.2% greater weight reduction (6 RCTs).51 …

… discussing urinary symptoms with patients prior to prescribing SGLT2is. Further research is critically needed to address these issues …

…ease, chronic kidney disease, non-liver cancer, CCI, metformin, DPP-4i, CLP-1RA, sulfonylureas, thiazolidinediones, insulin, ACEI/ARB,…

…erans Affairs healthcare system with type 2 diabetes initiating GLP-1RA (n=132 551) or sulfonylureas (n=201 136) between 1 January 2017…

…tients to receive new SGLT2i (RR 0.59, 95% CI 0.42 to 0.82) and GLP-1RA (RR 0.62, 95% CI 0.49 to 0.79) prescriptions; Hispanic patients…

… continuity, to maintain the cardioprotective effects seen with GLP-1RAs. Future research should focus on the generalisability of these …

…de (25 936), empagliflozin (715 802), sitagliptin (493 563) and glipizide (832 295) ( online supplemental eTable 1, 5–8). Baseline charac…

… history of receiving novel antidiabetic medications (SGLT2i or GLP-1RA). Sensitivity analyses were also conducted in participants with…